Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis

BACKGROUND: The association between immune checkpoint inhibitor (ICI) and outcomes of cancer patients with coronavirus disease 2019 (COVID-19) infection has yet to be systematically evaluated. This meta-analysis aims to investigate the effects of ICI treatment on COVID-19 prognosis, including mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarus, Gilbert, Budiman, Refael Alfa, Rinaldi, Ikhwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233621/
https://www.ncbi.nlm.nih.gov/pubmed/34173850
http://dx.doi.org/10.1007/s00262-021-02990-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233621/
https://www.ncbi.nlm.nih.gov/pubmed/34173850
http://dx.doi.org/10.1007/s00262-021-02990-9

Ejemplares similares